Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 16:2:1095225.
doi: 10.3389/frtra.2023.1095225. eCollection 2023.

COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study

Biagio Pinchera  1 , Antonio Riccardo Buonomo  1 , Emilia Trucillo  1 , Stefano Susini  1 , Alessia D'Agostino  1 , Isabella Di Filippo  1 , Anastasia Tanzillo  1 , Riccardo Villari  1 , Rosa Carrano  2 , Roberto Ivan Troisi  3 , Ivan Gentile  1
Affiliations

COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study

Biagio Pinchera et al. Front Transplant. .

Abstract

More than 2 years after the pandemic, the availability of vaccination and the use of monoclonal antibodies and direct antivirals have changed the fate of COVID-19, allowing for a better management of the disease, reducing hospitalization rates, and improving survival. This study aims to describe the outcome of COVID-19 in a cohort of solid organ transplant recipients and the impact of novel antivirals against SARS-CoV-2. We conducted an observational retrospective cohort study. We enrolled solid organ transplant recipients with COVID-19 attending the A.O.U. Federico II of Naples and followed up from January 2022 to July 2022. We enrolled 40 SOTs with COVID-19. Our experience highlights the favorable impact of therapies with antivirals and monoclonal antibodies in the early stages of COVID-19. Interesting data concern the impact of immunosuppressive therapy on COVID-19, in particular the role of Mycophenolate (associated with deterioration to severe COVID-19) and Everolimus (protective for progression to severe disease) needs to be investigated. Our experience also confirms the fundamental role of vaccination and in particular the importance of the booster dose.

Keywords: COVID-19; SARS-CoV-2; antiviral; solid organ transplant; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZH, Ramesh MS, et al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. (2021) 73(11):e4090–9. 10.1093/cid/ciaa1097 - DOI - PMC - PubMed
    1. Vinson AJ, Agarwal G, Dai R, Anzalone AJ, Lee SB, French E, et al. COVID-19 in solid organ transplantation: results of the national COVID cohort collaborative. Transplant Direct. (2021) 7(11):e775. 10.1097/TXD.0000000000001234 - DOI - PMC - PubMed
    1. Trapani S, Masiero L, Puoti F, Rota MC, Del Manso M, Lombardini L, et al. Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide population-based study. Am J Transplant. (2021) 21(7):2509–21. 10.1111/ajt.16428 - DOI - PMC - PubMed
    1. Pinchera B, Spirito L, Ferreri L, Rocca R, Celentano G, Buonomo AR, et al. SARS-CoV-2 in kidney transplant patients: a real-life experience. Front Med. (2022) 9:864865. 10.3389/fmed.2022.864865 - DOI - PMC - PubMed
    1. Okumura K, Nishida S, Dhand A. Trends in COVID-19 mortality among solid organ transplant recipients: implications for prevention. Transplantation. (2022) 106(8):e380-1. 10.1097/TP.0000000000004170 - DOI - PMC - PubMed